Immunome (NASDAQ:IMNM) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Immunome (NASDAQ:IMNM) from a sell rating to a hold rating in a research report report published on Saturday morning.

A number of other equities analysts have also recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Craig Hallum lifted their price target on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Stephens dropped their price target on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. Leerink Partners dropped their price target on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research note on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Immunome in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Immunome has an average rating of “Moderate Buy” and a consensus price target of $32.82.

Immunome Stock Down 5.2%

Immunome stock opened at $20.88 on Friday. The company’s 50-day moving average price is $21.96 and its 200-day moving average price is $21.19. Immunome has a twelve month low of $7.74 and a twelve month high of $27.65. The company has a market cap of $2.36 billion, a PE ratio of -8.77 and a beta of 2.11.

Immunome (NASDAQ:IMNM) last posted its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. As a group, sell-side analysts expect that Immunome will post -2.26 earnings per share for the current fiscal year.

Insider Buying and Selling at Immunome

In other Immunome news, insider Jack Higgins sold 9,438 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $21.64, for a total value of $204,238.32. Following the completion of the sale, the insider directly owned 22,000 shares of the company’s stock, valued at $476,080. The trade was a 30.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Max Rosett sold 65,000 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $21.92, for a total transaction of $1,424,800.00. Following the completion of the sale, the chief financial officer directly owned 54,037 shares of the company’s stock, valued at approximately $1,184,491.04. This trade represents a 54.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 139,438 shares of company stock valued at $2,964,664 in the last three months. Company insiders own 7.21% of the company’s stock.

Institutional Investors Weigh In On Immunome

Several large investors have recently added to or reduced their stakes in IMNM. T. Rowe Price Investment Management Inc. boosted its position in Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after buying an additional 5,003,824 shares during the period. JPMorgan Chase & Co. boosted its position in Immunome by 8,659.2% in the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after buying an additional 2,823,144 shares during the period. Primecap Management Co. CA boosted its position in Immunome by 55.2% in the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after buying an additional 1,667,432 shares during the period. Balyasny Asset Management L.P. purchased a new stake in Immunome in the 4th quarter valued at about $30,710,000. Finally, Sofinnova Investments Inc. boosted its position in Immunome by 271.2% in the 4th quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock valued at $34,765,000 after buying an additional 1,182,426 shares during the period. 44.58% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Immunome

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Immunome and kept a $40 price target, signaling meaningful upside expectations. Immunome (NASDAQ:IMNM) Given “Buy” Rating at HC Wainwright
• Positive Sentiment: Both HC Wainwright and Lifesci Capital raised earnings estimates for multiple 2026 and 2027 periods, suggesting improved operating expectations. Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Coherus Biosciences (CHRS)
• Neutral Sentiment: Analyst forecasts still show Immunome posting losses in 2026 and 2027, keeping attention on future clinical and commercial execution rather than near-term earnings.
• Neutral Sentiment: Lifesci Capital’s Q4 2026 estimate was still slightly negative despite being updated, reflecting cautious expectations for profitability.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.